Literature DB >> 22218504

[RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer].

C Nieder1.   

Abstract

Entities:  

Year:  2012        PMID： 22218504     DOI： 10.1007/s00066-011-0034-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

1.  Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

Authors:  Thomas Ruhstaller; Miklos Pless; Daniel Dietrich; Helmut Kranzbuehler; Roger von Moos; Peter Moosmann; Michael Montemurro; Paul M Schneider; Daniel Rauch; Oliver Gautschi; Walter Mingrone; Lucas Widmer; Roman Inauen; Peter Brauchli; Viviane Hess
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

2.  Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.

Authors:  Kristin Gurtner; Yvonne Deuse; Rebecca Bütof; Katja Schaal; Wolfgang Eicheler; Reinhard Oertel; Reidar Grenman; Howard Thames; Ala Yaromina; Michael Baumann; Mechthild Krause
Journal:  Radiother Oncol       Date:  2011-06-12       Impact factor: 6.280

3.  Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial.

Authors:  Alexandra D Jensen; Marc W Münter; Helge G Bischoff; Renate Haselmann; Uwe Haberkorn; Peter E Huber; Michael Thomas; Jürgen Debus; Klaus K Herfarth
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

4.  Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.

Authors:  Peter P Grimminger; Peter Danenberg; Kathrin Dellas; Dirk Arnold; Claus Rödel; Jean-Pascal Machiels; Karin Haustermans; Annelies Debucquoy; Vaneja Velenik; Christine Sempoux; Matej Bracko; Arnulf H Hölscher; Robert Semrau; Dongyun Yang; Kathleen Danenberg; Heinz-Josef Lenz; Daniel Vallböhmer
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

5.  Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.

Authors:  Howard Safran; Mohan Suntharalingam; Thomas Dipetrillo; Thomas Ng; L Austin Doyle; Mark Krasna; Angela Plette; Devon Evans; Harold Wanebo; Paul Akerman; Jeremy Spector; Nancy Kennedy; Teresa Kennedy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

6.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

7.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Authors:  Shirin Khambata-Ford; Christopher T Harbison; Lowell L Hart; Melissa Awad; Li-An Xu; Christine E Horak; Shaker Dakhil; Robert C Hermann; Thomas J Lynch; Martin R Weber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
  7 in total
  1 in total

1.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.